Xbrane Biopharma AB (XBRANE) — Net Asset Quality Index
Xbrane Biopharma AB (XBRANE) has a Net Asset Quality Index of 83.9% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of Skr642.61 Million minus total liabilities of Skr103.76 Million yields net assets of Skr538.85 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read how much debt does Xbrane Biopharma AB carry for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Xbrane Biopharma AB Net Asset Quality Index Over Time (2012–2025)
This chart shows how Xbrane Biopharma AB's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of June 2026, the index stands at 83.9%, representing net assets of Skr538.85 Million against total assets of Skr642.61 Million SEK. For live market cap and overall valuation, see how much is Xbrane Biopharma AB worth.
Annual Net Asset Quality Index for Xbrane Biopharma AB (2012–2025)
The table below presents the year-by-year Net Asset Quality Index for Xbrane Biopharma AB from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check asset allocation strategy of Xbrane Biopharma AB to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (SEK) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 83.5% | Skr560.65 Million | Skr671.62 Million | Skr110.97 Million | ▲ +58.7 pp |
| 2024 | 24.8% | Skr208.54 Million | Skr842.43 Million | Skr633.89 Million | ▼ -1.5 pp |
| 2023 | 26.2% | Skr171.34 Million | Skr653.51 Million | Skr482.17 Million | ▼ -35.3 pp |
| 2022 | 61.5% | Skr424.89 Million | Skr690.51 Million | Skr265.63 Million | ▼ -1.2 pp |
| 2021 | 62.7% | Skr431.74 Million | Skr688.43 Million | Skr256.69 Million | ▲ +7.1 pp |
| 2020 | 55.6% | Skr257.71 Million | Skr463.76 Million | Skr206.06 Million | ▲ +1.2 pp |
| 2019 | 54.4% | Skr184.32 Million | Skr338.94 Million | Skr154.62 Million | ▲ +21.5 pp |
| 2018 | 32.8% | Skr83.07 Million | Skr252.88 Million | Skr169.81 Million | ▼ -46.8 pp |
| 2017 | 79.7% | Skr88.41 Million | Skr110.96 Million | Skr22.55 Million | ▼ -11.2 pp |
| 2016 | 90.8% | Skr107.30 Million | Skr118.11 Million | Skr10.81 Million | ▲ +27.8 pp |
| 2015 | 63.1% | Skr47.51 Million | Skr75.33 Million | Skr27.82 Million | ▼ -31.1 pp |
| 2014 | 94.2% | Skr6.30 Million | Skr6.69 Million | Skr390.70K | ▼ -0.3 pp |
| 2013 | 94.5% | Skr8.69 Million | Skr9.20 Million | Skr505.44K | ▲ +81.1 pp |
| 2012 | 13.4% | Skr88.11K | Skr657.01K | Skr568.90K | — |